Preexposure chemoprophylaxis for HIV prevention in men who have sex with men RM Grant, JR Lama, PL Anderson, V McMahan, AY Liu, L Vargas, ... New England Journal of Medicine 363 (27), 2587-2599, 2010 | 5911 | 2010 |
Initiation of antiretroviral therapy in early asymptomatic HIV infection. JD Lundgren, AG Babiker, F Gordin, S Emery, B Grund, S Sharma, ... The New England journal of medicine 373 (9), 795-807, 2015 | 2183 | 2015 |
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society–USA Panel CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, BG Gazzard, ... Jama 283 (3), 381-390, 2000 | 1382 | 2000 |
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. P Braitstein, MW Brinkhof, F Dabis, M Schechter, A Boulle, P Miotti, ... Lancet (London, England) 367 (9513), 817-824, 2006 | 1360 | 2006 |
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study RM Grant, PL Anderson, V McMahan, A Liu, KR Amico, M Mehrotra, ... The Lancet infectious diseases 14 (9), 820-829, 2014 | 1304 | 2014 |
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel SM Hammer, MS Saag, M Schechter, JSG Montaner, RT Schooley, ... Jama 296 (7), 827-843, 2006 | 1156 | 2006 |
Initiation of antiretroviral therapy in early asymptomatic HIV infection Insight Start Study Group New England Journal of Medicine 373 (9), 795-807, 2015 | 1141 | 2015 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men PL Anderson, DV Glidden, A Liu, S Buchbinder, JR Lama, JV Guanira, ... Science translational medicine 4 (151), 151ra125-151ra125, 2012 | 1086 | 2012 |
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, ... Jama 288 (2), 222-235, 2002 | 985 | 2002 |
Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 908 | 2008 |
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, MS Hirsch, MS Saag, M Schechter, CCJ Carpenter, ... Jama 292 (2), 251-265, 2004 | 734 | 2004 |
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 605 | 2008 |
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 578 | 2008 |
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs FL Altice, A Kamarulzaman, VV Soriano, M Schechter, GH Friedland The Lancet 376 (9738), 367-387, 2010 | 555 | 2010 |
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries MWG Brinkhof, F Dabis, L Myer, DR Bangsberg, A Boulle, D Nash, ... Bulletin of the World Health Organization 86 (7), 559-567, 2008 | 435 | 2008 |
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ... Aids 27 (6), 973-979, 2013 | 424 | 2013 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial F Gordin, RE Chaisson, JP Matts, C Miller, M de Lourdes Garcia, R Hafner, ... Jama 283 (11), 1445-1450, 2000 | 392 | 2000 |
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 F Van Leth, P Phanuphak, E Stroes, B Gazzard, P Cahn, F Raffi, R Wood, ... PLoS medicine 1 (1), e19, 2004 | 341 | 2004 |
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission LG Bekker, G Alleyne, S Baral, J Cepeda, D Daskalakis, D Dowdy, ... The Lancet 392 (10144), 312-358, 2018 | 333 | 2018 |
HIV-1 DNA predicts disease progression and post-treatment virological control JP Williams, J Hurst, W Stöhr, N Robinson, H Brown, M Fisher, S Kinloch, ... elife 3, e03821, 2014 | 323 | 2014 |